RxDoctor Payments Data

Jacqueline Benoit, OD

Optometrist · Bala Cynwyd, PANPI 1174182950

Payments from drug & device makers

$2,609in general payments, 2019–2025

Across 68 payments — averaging $38.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$926
  • Oyster Point Pharma, Inc.$249
  • Tarsus Pharmaceuticals, Inc.$228
  • Glaukos Corporation$170
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$153
  • Bausch & Lomb Americas Inc.$150
  • plus $733 from 9 others

What the payments were for

  • Consulting fees$2008%
  • Speaking & faculty fees$1004%
  • Travel & lodging$35314%
  • Food & beverage$1,95775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,609 in reported general payments places this provider in the 80th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$93,272
Medicare patients
619
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine38$46,810
Cyclosporine21$14,858
LumiganBimatoprost18$8,383
Prednisolone Acetate32$1,623
Latanoprost116$963
Brimonidine Tartrate28$862
ErythromycinErythromycin Base70$711
Ofloxacin19$331
Timolol Maleate23$215
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$203
Doxycycline Hyclate14$182
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$149$55,19356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Bala Cynwyd

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →